Precision IBD, Inc.
Funding rounds
3 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Oct 2020 | $50 M | No. 3 | $50 to $250 million | equity | SEC | |
| Jun 2019 | $48 M | Issued in a merger or acquisition | $10 to $50 million | equity | SEC | |
| Nov 2018 | $10 M | No. 2 | $10 to $50 million | equity | SEC | |
| Sep 2017 | $4 M | No. 1 | $2 to $10 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Precision IBD, Inc. chose not to state its revenue in its newest notice of a funding round (Nov 2020).
SEC Form D · Nov 2020
The industry group it chose in its notices: Biotechnology.
SEC Form D · Nov 2020
That is all the official record says: Precision IBD, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).
Investors#
14 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| 72 Investment Holdings, LLC | Fund or asset manager | not stated | not stated | Held Series D-1 and D-2 preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Cedars Sinai Medical Center | Person | not stated | not stated | Held Series A, B, C, D-1 and D-2 preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Cohen Steven A/sac Capital Mgmt LP | Fund or asset manager | not stated | not stated | Held Series D-1 and D-2 preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Cormorant Asset Management, LP | Fund or asset manager | not stated | not stated | Held Series D-1 and D-2 preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Cormorant Global Healthcare Master Fund, LP | Fund or asset manager | not stated | not stated | Held Series D-1 and D-2 preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Cormorant Private Healthcare Fund III LP | Fund or asset manager | not stated | not stated | Held Series D-1 and D-2 preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Differentiated Ventures Investments, LLC | Venture capital | not stated | not stated | Held Series D-1 and D-2 preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Nestle SA | Company | not stated | not stated | Held Series C, D-1 and D-2 preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Perceptive Advisors LLC | Fund or asset manager | not stated | not stated | Held Series D-1 and D-2 preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Perceptive Life Sciences Master Fund LTD | Fund or asset manager | not stated | not stated | Held Series D-1 and D-2 preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Point72 Biotech Private Investments, LLC | Fund or asset manager | not stated | not stated | Held Series D-1 and D-2 preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| RTW Investments, LP | Fund or asset manager | not stated | not stated | Held Series D-1 and D-2 preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Societe des Produits Nestle S.A. | Company | not stated | not stated | Held Series C, D-1 and D-2 preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Tadataka Yamada | Person | not stated | not stated | Held Series B preferred stock, director (Form 3, 2021) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 22 investors.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Allison W. Luo, M.D. | Executive officer | Nov 2020 |
| Keith W. Marshall, Ph.D. | Executive officer | Nov 2020 |
| Lauren G. Otsuki | Executive officer | Nov 2020 |
| Laurens W. Kruidenier, Ph.D. | Executive officer | Nov 2020 |
| Mark Tachi McKenna | Executive officer | Nov 2020 |
| Allison Luo, M.D. | Executive officer | Apr 2020 |
| Chris Slavinsky | Executive officer | Apr 2020 |
| Lauren Otsuki | Executive officer | Apr 2020 |
| Laurens Kruidenier, Ph.D. | Executive officer | Apr 2020 |
| Mark Mckenna | Executive officer | Apr 2020 |
| Mike Walther | Executive officer | Apr 2020 |
| Thierry Dervieux, Pharm D., Ph.D. | Executive officer | Apr 2020 |
| Scott L. Glenn | Executive officer | Jul 2019 |
| Adam C. Stone | Director | Nov 2020 |
| James D. Laur | Director | Nov 2020 |
| Joseph C. Papa | Director | Nov 2020 |
| Joy Ghosh, Ph.D. | Director | Nov 2020 |
| Mark Tachi McKenna | Director | Nov 2020 |
| Martin Hendrix, Ph.D. | Director | Nov 2020 |
| Shierley C. Widjaja | Director | Nov 2020 |
| Tadataka Tachi Yamada, M.D. | Director | Nov 2020 |
| William C. Sandborn, M.D. | Director | Nov 2020 |
| Douglas Wall | Director | Apr 2020 |
| Gregory Behar | Director | Apr 2020 |
| James Laur | Director | Apr 2020 |
| Mark Mckenna | Director | Apr 2020 |
| Mark Stenhouse | Director | Apr 2020 |
| Shierley Widjaja | Director | Apr 2020 |
| Shlomo Melmed | Director | Apr 2020 |
| Tadataka Yamada, M.D. | Director | Apr 2020 |
| William Sandborn, M.D. | Director | Apr 2020 |
| Douglas F. Wall | Director | Jul 2019 |
| Gerald T. Proehl | Director | Jul 2019 |
| Gregory L. Behar | Director | Jul 2019 |
| Mark T. Stenhouse | Director | Jul 2019 |
| Scott L. Glenn | Director | Jul 2019 |
| Shierley T. Widjaja | Director | Jul 2019 |
| Shlomo T. Melmed | Director | Jul 2019 |
| Tadataka T. Yamada, M.D. | Director | Jul 2019 |
| William F. Sandborn, M.D. | Director | Jul 2019 |